Literature DB >> 18085720

The role of peptides in blood-brain barrier nanotechnology.

Meritxell Teixidó1, Ernest Giralt.   

Abstract

The blood-brain barrier (BBB) regulates the passage of molecules between the bloodstream and the brain. Overcoming the difficulty of delivery drugs to specific areas of the brain is a major challenge. The BBB exerts a neuroprotective function as it hinders the delivery of diagnostic and therapeutic agents to the brain. Here, we provide an overview of the way in which peptides and nanotechnology are being exploited in tandem to address this problem. Peptides can be used as specialised coatings able to transport nanoparticles with specific properties, such as targeting. The nanoparticle can also carry a peptide drug. Furthermore, peptides can be used in less conventional approaches such as all-peptide nanoparticles. In summary, the combined use of peptides and nanotechnology offers tremendous hope in the treatment of brain disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085720     DOI: 10.1002/psc.983

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  4 in total

Review 1.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

2.  Brain-targeted delivery of trans-activating transcriptor-conjugated magnetic PLGA/lipid nanoparticles.

Authors:  Xiangru Wen; Kai Wang; Ziming Zhao; Yifang Zhang; Tingting Sun; Fang Zhang; Jian Wu; Yanyan Fu; Yang Du; Lei Zhang; Ying Sun; YongHai Liu; Kai Ma; Hongzhi Liu; Yuanjian Song
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

Review 3.  Drug Nanocrystals: Focus on Brain Delivery from Therapeutic to Diagnostic Applications.

Authors:  Elide Zingale; Angela Bonaccorso; Claudia Carbone; Teresa Musumeci; Rosario Pignatello
Journal:  Pharmaceutics       Date:  2022-03-23       Impact factor: 6.525

4.  Identification of peptide ligands for targeting to the blood-brain barrier.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Gert Storm; Wim E Hennink; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-02-17       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.